SAN DIEGO, Dec. 3, 2012 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced the launch of
its redesigned and updated corporate website,www.adventrx.com. The
new website features clinician videos, patient resources, and
important news pertaining to sickle cell disease and ADVENTRX's
lead product candidate, ANX-188 (purified poloxamer 188).
In addition, ADVENTRX has launched Facebook, Twitter and YouTube
corporate pages to allow greater visibility with and access to
information by the investment, medical and patient communities.
Links to these social media sites can be found on the Company's
website.
"We are hopeful that www.adventrx.com will become a valuable
resource not only for our stockholders, but also for advocates,
educators, caregivers, and the millions of people around the world
who suffer from sickle cell disease. The ADVENTRX team is working
to initiate a phase 3 clinical trial in patients with sickle cell
disease and, once that trial begins, we will be the only company
with a new chemical entity in phase 3 for the treatment of sickle
cell disease. We believe this leadership position can serve as a
platform for us to make a significant, positive impact in this
important area," stated Brian M.
Culley, Chief Executive Officer of ADVENTRX.
As is common for website transitions, there is a domain name
system (DNS) propagation period during which internet service
providers direct users to a new site. This propagation period
typically is complete within 48 hours. Frequent or past
visitors to www.adventrx.com may need to clear their web browser's
cache to ensure they are viewing the updated corporate website.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company
developing proprietary product candidates to treat various diseases
and conditions. The Company's lead product candidate, ANX-188, has
potential to reduce ischemic tissue injury and end-organ damage by
restoring microvascular function, which is compromised in a wide
range of serious and life-threatening diseases and
conditions. The Company initially is developing ANX-188 as a
treatment for complications arising from sickle cell disease. More
information can be found on the Company's website at
www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements that are based on ADVENTRX's current
expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements regarding the value of
ADVENTRX's new website to third party users, the timing of
ADVENTRX's planned phase 3 study of ANX-188 and ADVENTRX's
potential leadership position in development of therapies to treat
sickle cell disease. Among the factors that could cause or
contribute to material differences between ADVENTRX's actual
results and those indicated from the forward-looking statements are
risks and uncertainties inherent in ADVENTRX's business, including,
but not limited to: the availability of and timeliness of updates
to information in ADVENTRX's new website and the third party
resources linked to therein; the potential for delays in the
commencement or completion of ADVENTRX's planned clinical studies,
including as a result of difficulties in completing manufacturing
process development activities, manufacturing clinical trial
material, meeting applicable regulatory requirements for clinical
trial material, meeting applicable requirements of institutional
review boards overseeing clinical study sites, or being subject to
a "clinical hold"; the risk of suspension or termination of a
clinical study, including due to lack of adequate funding or a
"clinical hold"; ADVENTRX's reliance on contract research
organizations (CROs) and other third parties to assist in the
conduct of important aspects of its clinical studies, and that such
third parties may fail to perform as expected; the risk that
planned clinical studies are not successfully executed and/or do
not successfully demonstrate the safety or efficacy of the
investigational drug; the risk that, even if clinical studies are
successful, the FDA determines they are not sufficient to support a
new drug application; ADVENTRX's ability to obtain additional
funding on a timely basis or on acceptable terms, or at all; the
potential for ADVENTRX to delay, reduce or discontinue current
and/or planned development activities, including clinical studies,
partner its product candidates at inopportune times or pursue less
expensive but higher-risk development paths if it is unable to
raise sufficient additional capital as needed; the risk that the
FDA does not grant marketing approval of ADVENTRX's product
candidates, including ANX-188, on a timely basis, or at all; and
other risks and uncertainties more fully described in ADVENTRX's
press releases and periodic filings with the Securities and
Exchange Commission. ADVENTRX's public filings with the Securities
and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. ADVENTRX
does not intend to revise or update any forward-looking statement
set forth in this press release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
(Logo:
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)
SOURCE ADVENTRX Pharmaceuticals, Inc.